S&P 500   2,592.00 (-1.32%)
DOW   22,062.66 (-1.19%)
QQQ   190.91 (-0.59%)
AAPL   255.59 (+0.31%)
FB   167.99 (+1.23%)
MSFT   159.44 (-0.49%)
GOOGL   1,162.44 (+1.41%)
AMZN   1,975.71 (+0.60%)
CGC   14.43 (-0.21%)
NVDA   263.36 (-0.84%)
BABA   194.41 (+1.64%)
MU   43.10 (-3.19%)
GE   7.91 (+0.25%)
TSLA   523.31 (+4.22%)
AMD   46.55 (-2.74%)
T   29.37 (-2.84%)
ACB   0.90 (+1.12%)
F   4.95 (-1.59%)
NFLX   374.44 (+0.94%)
BAC   21.81 (-1.04%)
GILD   74.56 (-1.82%)
DIS   98.11 (-1.69%)
S&P 500   2,592.00 (-1.32%)
DOW   22,062.66 (-1.19%)
QQQ   190.91 (-0.59%)
AAPL   255.59 (+0.31%)
FB   167.99 (+1.23%)
MSFT   159.44 (-0.49%)
GOOGL   1,162.44 (+1.41%)
AMZN   1,975.71 (+0.60%)
CGC   14.43 (-0.21%)
NVDA   263.36 (-0.84%)
BABA   194.41 (+1.64%)
MU   43.10 (-3.19%)
GE   7.91 (+0.25%)
TSLA   523.31 (+4.22%)
AMD   46.55 (-2.74%)
T   29.37 (-2.84%)
ACB   0.90 (+1.12%)
F   4.95 (-1.59%)
NFLX   374.44 (+0.94%)
BAC   21.81 (-1.04%)
GILD   74.56 (-1.82%)
DIS   98.11 (-1.69%)
S&P 500   2,592.00 (-1.32%)
DOW   22,062.66 (-1.19%)
QQQ   190.91 (-0.59%)
AAPL   255.59 (+0.31%)
FB   167.99 (+1.23%)
MSFT   159.44 (-0.49%)
GOOGL   1,162.44 (+1.41%)
AMZN   1,975.71 (+0.60%)
CGC   14.43 (-0.21%)
NVDA   263.36 (-0.84%)
BABA   194.41 (+1.64%)
MU   43.10 (-3.19%)
GE   7.91 (+0.25%)
TSLA   523.31 (+4.22%)
AMD   46.55 (-2.74%)
T   29.37 (-2.84%)
ACB   0.90 (+1.12%)
F   4.95 (-1.59%)
NFLX   374.44 (+0.94%)
BAC   21.81 (-1.04%)
GILD   74.56 (-1.82%)
DIS   98.11 (-1.69%)
S&P 500   2,592.00 (-1.32%)
DOW   22,062.66 (-1.19%)
QQQ   190.91 (-0.59%)
AAPL   255.59 (+0.31%)
FB   167.99 (+1.23%)
MSFT   159.44 (-0.49%)
GOOGL   1,162.44 (+1.41%)
AMZN   1,975.71 (+0.60%)
CGC   14.43 (-0.21%)
NVDA   263.36 (-0.84%)
BABA   194.41 (+1.64%)
MU   43.10 (-3.19%)
GE   7.91 (+0.25%)
TSLA   523.31 (+4.22%)
AMD   46.55 (-2.74%)
T   29.37 (-2.84%)
ACB   0.90 (+1.12%)
F   4.95 (-1.59%)
NFLX   374.44 (+0.94%)
BAC   21.81 (-1.04%)
GILD   74.56 (-1.82%)
DIS   98.11 (-1.69%)
Log in

NASDAQ:OMER - Omeros Stock Price, Forecast & News

$12.47
+1.07 (+9.39 %)
(As of 03/31/2020 01:26 PM ET)
Today's Range
$11.49
Now: $12.47
$13.00
50-Day Range
$9.03
MA: $13.23
$19.72
52-Week Range
$8.50
Now: $12.47
$20.92
Volume29,663 shs
Average Volume1.55 million shs
Market Capitalization$676.00 million
P/E RatioN/A
Dividend YieldN/A
Beta2.56
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington.
Read More
Omeros logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.81 million
Book Value($2.19) per share

Profitability

Net Income$-84,490,000.00

Miscellaneous

Employees236
Market Cap$676.00 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.


Omeros (NASDAQ:OMER) Frequently Asked Questions

How has Omeros' stock been impacted by COVID-19 (Coronavirus)?

Omeros' stock was trading at $15.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OMER stock has decreased by 17.1% and is now trading at $12.47. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Omeros?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Omeros.

When is Omeros' next earnings date?

Omeros is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Omeros.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) issued its quarterly earnings results on Monday, March, 2nd. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.24. The biopharmaceutical company had revenue of $33.42 million for the quarter, compared to analyst estimates of $31.38 million. View Omeros' earnings history.

What price target have analysts set for OMER?

5 brokerages have issued 1-year target prices for Omeros' stock. Their forecasts range from $22.00 to $34.00. On average, they anticipate Omeros' share price to reach $26.75 in the next twelve months. This suggests a possible upside of 114.5% from the stock's current price. View analysts' price targets for Omeros.

Has Omeros been receiving favorable news coverage?

Press coverage about OMER stock has been trending negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Omeros earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutOmeros.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the following people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $12.47.

How big of a company is Omeros?

Omeros has a market capitalization of $676.00 million and generates $111.81 million in revenue each year. The biopharmaceutical company earns $-84,490,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Omeros employs 236 workers across the globe. View additional information about Omeros.

What is Omeros' official website?

The official website for Omeros is http://www.omeros.com/.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  719 (Vote Outperform)
Underperform Votes:  489 (Vote Underperform)
Total Votes:  1,208
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Featured Article: Blue-Chip Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel